Clear Trail Advisors LLC Acquires New Position in Merck & Co., Inc. $MRK

Clear Trail Advisors LLC acquired a new position in Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 75,671 shares of the company’s stock, valued at approximately $7,965,000. Merck & Co., Inc. comprises 1.8% of Clear Trail Advisors LLC’s portfolio, making the stock its 16th biggest position.

A number of other institutional investors also recently made changes to their positions in the business. Darwin Wealth Management LLC boosted its position in Merck & Co., Inc. by 237.4% during the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares during the period. Kilter Group LLC bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $27,000. Bare Financial Services Inc lifted its stake in shares of Merck & Co., Inc. by 51.9% in the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after acquiring an additional 125 shares during the last quarter. Barnes Dennig Private Wealth Management LLC boosted its holdings in Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after acquiring an additional 266 shares during the period. Finally, Evolution Wealth Management Inc. purchased a new stake in Merck & Co., Inc. during the 2nd quarter valued at about $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on MRK shares. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. The Goldman Sachs Group upped their price target on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Cantor Fitzgerald increased their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. UBS Group raised their price target on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Citigroup upped their price objective on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $127.13.

Insider Activity at Merck & Co., Inc.

In other news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the transaction, the insider directly owned 21,197 shares of the company’s stock, valued at $2,583,278.39. This represents a 41.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 320,176 shares of company stock valued at $38,281,735 over the last three months. 0.09% of the stock is owned by insiders.

Merck & Co., Inc. Price Performance

MRK opened at $115.65 on Tuesday. The stock has a fifty day simple moving average of $115.94 and a two-hundred day simple moving average of $101.09. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The company has a market cap of $285.93 billion, a price-to-earnings ratio of 15.89, a price-to-earnings-growth ratio of 2.21 and a beta of 0.27. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. During the same period last year, the business earned $1.72 earnings per share. The business’s revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.